Neurogene INC 8-K filings

Neurogene Inc. announced positive second quarter 2026 financial results, highlighting significant advancements in its NGN-401 program for Rett syndrome, including compelling clinical data and an extended cash runway.

Neurogene announces updated positive Phase 1/2 clinical data for NGN-401 gene therapy in Rett syndrome, showing durable developmental milestone gains and a well-tolerated safety profile.

Neurogene Inc. announced the successful completion of dosing in its Embolden registrational trial for NGN-401, a gene therapy for Rett syndrome, exceeding enrollment targets.

Neurogene Inc. shareholders re-elected two directors and ratified the appointment of Deloitte & Touche LLP at the 2026 Annual Meeting.

Neurogene Inc. announced first quarter 2026 financial results, highlighting significant progress in its Embolden registrational trial for NGN-401 in Rett syndrome, with approximately 90% of participants dosed.

Neurogene Inc. announced the appointment of Christy Shafer as Chief Commercial Officer and Christine Mikail to its Board of Directors, bolstering its leadership team for the advancement of its gene therapy programs.

Neurogene Inc. announced full year 2025 financial results and significant progress in its NGN-401 gene therapy program for Rett syndrome, including 100% enrollment in its registrational trial and FDA Breakthrough Therapy designation.

Neurogene Inc. announced that its investigational gene therapy, NGN-401, received FDA Breakthrough Therapy designation for Rett syndrome based on promising Phase 1/2 clinical data.

Neurogene Inc. announced significant progress in its NGN-401 gene therapy program for Rett syndrome, including dosing in its registrational trial and anticipated key milestones for 2026.

Neurogene Inc. reported positive interim data from its NGN-401 Phase 1/2 gene therapy trial for Rett syndrome, showing multidomain, durable gains, alongside its third quarter 2025 financial results.

Neurogene Inc. announced positive interim clinical data for its NGN-401 gene therapy in pediatric Rett syndrome patients, demonstrating durable, multidomain functional gains and a favorable safety profile.

Neurogene Inc. announced the dosing of the first patient in its Embolden registrational trial for NGN-401, a gene therapy for Rett syndrome, marking a significant step towards a potential first-in-class treatment.

Neurogene completes FDA discussions for its NGN-401 Rett syndrome gene therapy registrational trial and plans to initiate dosing in Q4 2025, supported by positive preclinical data.

Neurogene Inc. announced second quarter 2025 financial results and significant progress in its NGN-401 gene therapy program for Rett syndrome, including FDA agreement on its registrational trial design and an extended cash runway into early 2028.

Neurogene Inc. announced written agreement from the FDA on the registrational trial design for its NGN-401 gene therapy for Rett syndrome, alongside an extension of its cash runway into early 2028.

Neurogene Inc. stockholders approved amendments to the company's 2023 Equity Incentive Plan and 2023 Employee Stock Purchase Plan, significantly increasing the shares available for equity compensation and clarifying share reserve calculations.

Neurogene Inc. has filed an 8-K announcing an updated corporate presentation highlighting compelling interim Phase 1/2 clinical data for NGN-401 in Rett syndrome, demonstrating durable improvements across multiple core domains and progress towards registrational trials.

Neurogene Inc. announces its first quarter 2025 financial results, highlights progress on its NGN-401 gene therapy program for Rett syndrome, and provides updates on upcoming milestones.

Neurogene Inc. amended its agreement with Baker Bros. Advisors LP, increasing the ownership threshold required for Baker Bros. to nominate a director from 12.5% to 14.9% and exchanged common stock for prefunded warrants with existing stockholders.

Neurogene reports financial results for Q4 and full year 2024, highlighting progress in the NGN-401 Rett syndrome trial and a cash runway into the second half of 2027.

Neurogene Inc. released an updated corporate presentation highlighting positive interim clinical data from its NGN-401 gene therapy trial for Rett syndrome, showing improvements across multiple functional domains.

Neurogene reports the death of a patient in its Phase 1/2 Rett syndrome trial due to complications from a hyperinflammatory syndrome, leading to a revised dosage strategy for future trials.

Neurogene reported positive interim clinical data for its NGN-401 gene therapy in Rett syndrome, secured $200 million in funding, and provided updates on its clinical programs.

Neurogene has paused the high-dose arm of its NGN-401 gene therapy trial for Rett syndrome following a serious adverse event in a participant, while continuing the low-dose arm after FDA review.

Neurogene reports positive interim efficacy data from the first four participants in the low-dose cohort of its NGN-401 gene therapy clinical trial for Rett syndrome, showing improvements in multiple key areas.

Neurogene has successfully raised $200 million through a private placement, extending its operational runway into the second half of 2027.

Neurogene reported its second quarter 2024 financial results, highlighted the FDA's RMAT designation and START program selection for its NGN-401 gene therapy, and provided updates on its clinical programs.

Neurogene's NGN-401 gene therapy for Rett syndrome has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA, based on promising preliminary clinical trial data.

Neurogene Inc. has released an updated corporate presentation detailing progress in its clinical trials for Rett syndrome and CLN5 Batten disease, along with advancements in its proprietary gene therapy technology.

Neurogene has dosed the first patient in the high-dose cohort of its NGN-401 gene therapy trial for Rett syndrome, with the therapy being well-tolerated, and low-dose data continues to show a favorable safety profile.